The BAMM2 (BRAF Autophagy MEK inhibition in Melanoma) Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib with or without Hydroxychloroquine in Advanced BRAFV600E/K Melanoma with elevated LDH
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Advanced Melanoma
-
Age: Between 18 - 100 Years
-
Gender: Male or Female
-
Other Inclusion Criteria:
- Patient must have locally advanced unresectable stage IIIC to stage IV melanoma.
- Patient must have BRAFV600E or BRAFV600K tumor genotype based on a CLIA approved assay.
- Patient must have serum LDH > Upper limit of normal per institution standards.
- Patient must have an ECOG performance status of 0 or 1.
You may not be eligible for this study if the following are true:
-
- Patients who are known to be experiencing an objective partial response to immunotherapy at the time of study enrollment.
- History of interstitial lung disease (ILD) or chronic pneumonitis.
- Previously documented retinal vein occlusion.
- History or evidence of increased cardiovascular risk.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.